We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
IQVIA has come out with a new report that looks back at the historic timelines achieved by the COVID-19 vaccine trials, outlining lessons learned from the unprecedented research effort that have application now and in future research. Read More
After pocketing positive phase 3 topline results, Novartis will ask regulators to approve its checkpoint inhibitor tislelizumab as first-line add-on therapy for patients with previously untreatable esophageal squamous-cell carcinoma (ESCC). Read More
Shionogi’s investigative COVID-19 therapy is showing some promise in early laboratory studies, rapidly clearing viral levels and decreasing the period of active shedding, the company reported at the European Congress of Clinical Microbiology and Infectious Diseases. Read More
A large postmarket study suggests that some patients with multiple sclerosis (MS) who are stable on Biogen’s Tysabri (natalizumab) can safely extend their dosing interval from four to six weeks. Read More
Roche’s breast cancer drug candidate giredestrant, an oral selective estrogen receptor degrader (SERD), didn’t meets its primary endpoint of progression-free survival in a phase 2 trial of patients with an advanced form of breast cancer, said the company in an Securities and Exchange Commission (SEC) filing yesterday. Read More
Scynexis said two phase 3 studies of its antifungal drug, ibrexafungerp, showed the drug’s efficacy against difficult-to-treat drug-resistant fungal infections. Read More
The company is seeking approval for the vaccine from the FDA, the European Medicines Agency and the UK’s Medicines and Healthcare products Regulatory Agency. Read More
Evusheld, AstraZeneca’s dual-antibody injection, reduced the risk of COVID-19 by more than 76 percent at three months and by 83 percent at six months after immunization, new trial results show. Read More